AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Lumigan/Ganfort (bimatoprost) by Year
Lumigan/Ganfort (bimatoprost) — International reported growth YoY (%) (%)
AbbVie Lumigan/Ganfort (bimatoprost): -8.7% in FY2025, down 2.3 pts from a year earlier.
Latest, FY2025
-8.7%
Period ended Dec 31, 2025
Change on a year earlier
-2.3 pts
-6.4% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Lumigan/Ganfort | 189 | 221 | 410 | 1.2 | (8.7) | (4.4) | (8.3) | (4.2)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lumigan/Ganfort (bimatoprost) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8.7% | -2.3 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | -6.4% | -1.6 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -4.8% | +6.5 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | -11.3% | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Lumigan/Ganfort (bimatoprost) (%), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lumigan-intl-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.